We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Icomes Lab Demonstrates World's Smallest and Lightest Electronic Pipette for PCR Testing at MEDICA 2021

By LabMedica International staff writers
Posted on 18 Nov 2021
Print article
Image: Pipetty Electronic Pipette (Photo courtesy of ICOMES LAB Co., Ltd.)
Image: Pipetty Electronic Pipette (Photo courtesy of ICOMES LAB Co., Ltd.)

ICOMES LAB Co., Ltd. (Iwate, Japan) demonstrated the world's smallest and lightest electronic pipette with a length of 135mm and a weight of 75g at MEDICA 2021.

ICOMES pipetty is the world's smallest, lightest, pen-type electronic pipette. This high-precision lightweight electronic pipette is ideal for continuous dispensing of PCR testing. It continuously dispenses a fixed number of times automatically and compensates a dispensing volume for preventing accuracy deterioration due to hand warming.

ICOMES also demonstrated its pipetty Smart electric pipette that can be controlled by a smartphone app. pipetty Smart is the world's first pipette with wireless communication function.Equipped with Bluetooth technology, it reduces the burden of routine work on the operator by setting the dispensing protocol. It automatically creates a log file after dispensing operation, leaving evidence for post-checks. pipetty Smart is equipped with a smartphone numeric keypad and voice input function to improve work efficiency.

Related Links:
ICOMES LAB Co., Ltd. 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
New
3-Position Stirrer
ST-200 and SHP-200 Series
New
FAP Immunoassay
Quantikine QuicKit Human FAP ELISA

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.